Hair-loss drug tied to suicides, depression and anxiety in global study

A recent review published in The Journal of Clinical Psychiatry by Professor Mayer Brezis asserts that the hair-loss drug Finasteride carries significant, long-unaddressed risks of depression, anxiety, and suicidality, urging its removal from the market. The report criticizes a two-decade delay by regulators and manufacturers, including Organon (formerly Merck), in fully acknowledging these adverse effects, which Brezis estimates have impacted hundreds of thousands globally. This development poses considerable regulatory scrutiny and potential litigation risk for companies producing Finasteride, despite Organon's defense of its product's safety and efficacy.

Analysis

Professor Mayer Brezis's recent review in The Journal of Clinical Psychiatry critically highlights significant, long-standing neuropsychiatric risks associated with Finasteride, a widely prescribed hair-loss drug. The review asserts that depression, anxiety, and suicidality are genuine risks, citing evidence dating back to 2002 and criticizing a two-decade delay by regulators and manufacturers in fully acknowledging these adverse effects. Brezis estimates hundreds of thousands may have endured depression and hundreds may have died by suicide globally due to the drug.

Organon (OGN), formerly part of Merck (MRK) and manufacturer of Propecia and Proscar, defends the safety and efficacy of its finasteride products, referencing thorough regulatory reviews and ongoing post-marketing surveillance. However, the FDA acknowledged depression as a potential side effect in 2011 and suicidality in 2022, with Brezis arguing the reported suicide numbers are severely underestimated. This creates a direct conflict between academic findings, regulatory acknowledgments, and corporate statements.

The strongly negative sentiment (-0.75) and pessimistic tone surrounding Finasteride, coupled with themes of "Regulation & Legislation" and "Legal & Litigation," indicate heightened scrutiny and potential financial repercussions. Brezis's recommendation for patients to "stay away from this medication" and for the FDA to "take it off the market" underscores the severity of the perceived risks, suggesting increased regulatory pressure and product liability exposure for manufacturers.

Key Decisions for Investors

• Investors should monitor for potential regulatory actions, such as increased labeling requirements, restrictions, or market withdrawal of Finasteride, which could significantly impact manufacturers like Organon (OGN) and Merck (MRK).
• Assess the heightened litigation risk for companies involved in Finasteride production, given the strong claims of delayed acknowledgment of severe adverse effects and potential product liability lawsuits.
• Re-evaluate exposure to pharmaceutical companies with significant revenue streams from Finasteride or similar drugs, considering the negative sentiment, potential for reputational damage, and the implications for company fundamentals.